Nuvation Bio Statistics
Total Valuation
Nuvation Bio has a market cap or net worth of $2.18 billion. The enterprise value is $1.94 billion.
| Market Cap | 2.18B |
| Enterprise Value | 1.94B |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nuvation Bio has 351.12 million shares outstanding. The number of shares has increased by 4.49% in one year.
| Current Share Class | 350.12M |
| Shares Outstanding | 351.12M |
| Shares Change (YoY) | +4.49% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | 17.52% |
| Owned by Institutions (%) | 58.31% |
| Float | 263.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.85 |
| Forward PS | 10.15 |
| PB Ratio | 8.57 |
| P/TBV Ratio | 8.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.37, with a Debt / Equity ratio of 1.64.
| Current Ratio | 8.37 |
| Quick Ratio | 7.98 |
| Debt / Equity | 1.64 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.16 |
Financial Efficiency
Return on equity (ROE) is -47.81% and return on invested capital (ROIC) is -13.80%.
| Return on Equity (ROE) | -47.81% |
| Return on Assets (ROA) | -12.36% |
| Return on Invested Capital (ROIC) | -13.80% |
| Return on Capital Employed (ROCE) | -20.92% |
| Weighted Average Cost of Capital (WACC) | 11.42% |
| Revenue Per Employee | $557,049 |
| Profits Per Employee | -$491,236 |
| Employee Count | 305 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 1.96 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +138.31% in the last 52 weeks. The beta is 1.52, so Nuvation Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.52 |
| 52-Week Price Change | +138.31% |
| 50-Day Moving Average | 5.88 |
| 200-Day Moving Average | 5.81 |
| Relative Strength Index (RSI) | 50.23 |
| Average Volume (20 Days) | 6,193,173 |
Short Selling Information
The latest short interest is 53.42 million, so 15.22% of the outstanding shares have been sold short.
| Short Interest | 53.42M |
| Short Previous Month | 54.36M |
| Short % of Shares Out | 15.22% |
| Short % of Float | 20.26% |
| Short Ratio (days to cover) | 7.80 |
Income Statement
In the last 12 months, Nuvation Bio had revenue of $169.90 million and -$149.83 million in losses. Loss per share was -$0.44.
| Revenue | 169.90M |
| Gross Profit | 149.81M |
| Operating Income | -137.63M |
| Pretax Income | -149.83M |
| Net Income | -149.83M |
| EBITDA | -135.48M |
| EBIT | -137.63M |
| Loss Per Share | -$0.44 |
Balance Sheet
The company has $660.96 million in cash and $416.26 million in debt, with a net cash position of $244.69 million or $0.70 per share.
| Cash & Cash Equivalents | 660.96M |
| Total Debt | 416.26M |
| Net Cash | 244.69M |
| Net Cash Per Share | $0.70 |
| Equity (Book Value) | 253.86M |
| Book Value Per Share | 0.73 |
| Working Capital | 639.68M |
Cash Flow
In the last 12 months, operating cash flow was -$120.52 million and capital expenditures -$403,000, giving a free cash flow of -$120.93 million.
| Operating Cash Flow | -120.52M |
| Capital Expenditures | -403,000 |
| Depreciation & Amortization | 2.15M |
| Net Borrowing | 182.69M |
| Free Cash Flow | -120.93M |
| FCF Per Share | -$0.34 |
Margins
Gross margin is 88.18%, with operating and profit margins of -81.00% and -88.19%.
| Gross Margin | 88.18% |
| Operating Margin | -81.00% |
| Pretax Margin | -88.19% |
| Profit Margin | -88.19% |
| EBITDA Margin | -79.74% |
| EBIT Margin | -81.00% |
| FCF Margin | n/a |
Dividends & Yields
Nuvation Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.49% |
| Shareholder Yield | -4.49% |
| Earnings Yield | -6.86% |
| FCF Yield | -5.54% |
Analyst Forecast
The average price target for Nuvation Bio is $13.11, which is 110.77% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.11 |
| Price Target Difference | 110.77% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 85.33% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nuvation Bio has an Altman Z-Score of 0.48 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.48 |
| Piotroski F-Score | 3 |